Cargando…

Long‐term safety and treatment effects of cannabidiol in children and adults with treatment‐resistant epilepsies: Expanded access program results

OBJECTIVE: Since 2014, cannabidiol (CBD) has been administered to patients with treatment‐resistant epilepsies (TREs) in an ongoing expanded‐access program (EAP). We report interim results on the safety and efficacy of CBD in EAP patients treated through December 2016. METHODS: Twenty‐five US‐based...

Descripción completa

Detalles Bibliográficos
Autores principales:	Szaflarski, Jerzy P., Bebin, Elizabeth Martina, Comi, Anne M., Patel, Anup D., Joshi, Charuta, Checketts, Daniel, Beal, Jules C., Laux, Linda C., De Boer, Lisa M., Wong, Matthew H., Lopez, Merrick, Devinsky, Orrin, Lyons, Paul D., Zentil, Pilar Pichon, Wechsler, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Full‐length Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175436/ https://www.ncbi.nlm.nih.gov/pubmed/29998598 http://dx.doi.org/10.1111/epi.14477

Ejemplares similares

Long‐term cannabidiol treatment in patients with Dravet syndrome: An open‐label extension trial
por: Devinsky, Orrin, et al.
Publicado: (2018)

Cannabidiol in patients with Lennox‐Gastaut syndrome: Interim analysis of an open‐label extension study
por: Thiele, Elizabeth, et al.
Publicado: (2019)

Time to onset of cannabidiol treatment effect and resolution of adverse events in tuberous sclerosis complex: Post hoc analysis of randomized controlled phase 3 trial GWPCARE6
por: Wu, Joyce Y., et al.
Publicado: (2022)

Final analysis of potential drug–drug interactions between highly purified cannabidiol and anti‐seizure medications in an open‐label expanded access program
por: Gaston, Tyler E., et al.
Publicado: (2023)

Cannabidiol efficacy independent of clobazam: Meta‐analysis of four randomized controlled trials
por: Devinsky, Orrin, et al.
Publicado: (2020)

Pharmacogenetic Predictors of Cannabidiol Response and Tolerability in Treatment‐Resistant Epilepsy
por: Davis, Brittney H., et al.
Publicado: (2021)

Time to onset of cannabidiol treatment effects in Dravet syndrome: Analysis from two randomized controlled trials
por: Madan Cohen, Jennifer, et al.
Publicado: (2021)

Time to onset of cannabidiol (CBD) treatment effect in Lennox–Gastaut syndrome: Analysis from two randomized controlled trials
por: Privitera, Michael, et al.
Publicado: (2021)

Cannabidiol attenuates inflammatory impairment of intestinal cells expanding biomaterial-based therapeutic approaches
por: Boehm, Elisa, et al.
Publicado: (2023)

Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome
por: Devinsky, Orrin, et al.
Publicado: (2018)

Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial
por: Thiele, Elizabeth A., et al.
Publicado: (2020)

An interaction between warfarin and cannabidiol, a case report
por: Grayson, Leslie, et al.
Publicado: (2017)

Seizure‐related deaths in children: The expanding spectrum
por: Harowitz, Jenna, et al.
Publicado: (2021)

Long‐term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open‐label extension trial
por: Thiele, Elizabeth A., et al.
Publicado: (2021)

A preliminary study of the effects of cannabidiol (CBD) on brain structure in patients with epilepsy
por: Sharma, Ayushe A., et al.
Publicado: (2019)

Personalized medicine: Vinpocetine to reverse effects of GABRB3 mutation
por: Billakota, Santoshi, et al.
Publicado: (2019)

Cannabidiol in the Treatment of Epilepsy
por: von Wrede, Randi, et al.
Publicado: (2021)

Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials
por: Gunning, Boudewijn, et al.
Publicado: (2020)

Factors related to substance use treatment attendance after peer recovery coach intervention in the emergency department
por: Ware, Orrin D., et al.
Publicado: (2022)

Clinical implications of trials investigating drug‐drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs
por: Patsalos, Philip N., et al.
Publicado: (2020)

Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions
por: Anderson, Lyndsey L., et al.
Publicado: (2019)

Cannabidiol reduces seizures following CNS infection with Theiler's murine encephalomyelitis virus
por: Patel, Dipan C., et al.
Publicado: (2019)

Cannabidiol as a treatment for epilepsy
por: Pickrell, William O., et al.
Publicado: (2017)

Responsive neurostimulation targeting the anterior nucleus of the thalamus in 3 patients with treatment‐resistant multifocal epilepsy
por: Elder, Christopher, et al.
Publicado: (2019)

Cannabidiol reduces seizures and associated behavioral comorbidities in a range of animal seizure and epilepsy models
por: Patra, Pabitra Hriday, et al.
Publicado: (2018)

Observational study of medical marijuana as a treatment for treatment‐resistant epilepsies
por: Devinsky, Orrin, et al.
Publicado: (2022)

Potential of Cannabidiol for the Treatment of Viral Hepatitis
por: Lowe, Henry I. C., et al.
Publicado: (2017)

Cannabidiol Treatment for Refractory Epilepsies in Pediatrics
por: Raucci, Umberto, et al.
Publicado: (2020)

Cannabidiol as a potential treatment for psychosis
por: Davies, Cathy, et al.
Publicado: (2019)

Editorial: Cannabidiol Treatment in Neurotherapeutic Interventions
por: Gonzalez-Cuevas, Gustavo, et al.
Publicado: (2021)

Cannabidiol: potential in treatment of neurological diseases, flax as a possible natural source of cannabidiol
por: Storozhuk, Maksim V.
Publicado: (2023)

Seizure Clusters: Morbidity and Mortality
por: Bauman, Kristie, et al.
Publicado: (2021)

An In Silico Study for Expanding the Utility of Cannabidiol in Alzheimer’s Disease Therapeutic Development
por: Choi, Kyudam, et al.
Publicado: (2023)

Adjunctive therapy for the treatment of primary generalized tonic-clonic seizures: focus on oncedaily lamotrigine
por: Steinbaugh, Linda, et al.
Publicado: (2010)

Results From an Italian Expanded Access Program on Cannabidiol Treatment in Highly Refractory Dravet Syndrome and Lennox–Gastaut Syndrome
por: Iannone, Luigi Francesco, et al.
Publicado: (2021)

Primary care provider attitudes, experiences and practices about cannabidiol (CBD) and barriers to patient-provider communication about CBD use: A qualitative study
por: Sharma, Pravesh, et al.
Publicado: (2022)

SUDEP: Advances and Challenges
por: Devinsky, Orrin, et al.
Publicado: (2020)

Identifying and evaluating novel treatment targets for the development of evidence-based interventions for functional neurological disorder
por: Fobian, Aaron D., et al.
Publicado: (2021)

Inadequate Regulation Contributes to Mislabeled Online Cannabidiol Products
por: Freedman, Daniel A., et al.
Publicado: (2018)

Post-traumatic epilepsy: current and emerging treatment options
por: Szaflarski, Jerzy P, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_qsmfj7thus6lqif8ejph40gcus